Literature DB >> 20133888

Excess betaCTF, not Abeta: the culprit in Alzheimer-related endocytic dysfunction.

W Sue T Griffin1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20133888      PMCID: PMC2824414          DOI: 10.1073/pnas.0913922107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  17 in total

1.  Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E.

Authors:  S W Barger; A D Harmon
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

2.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy.

Authors:  Anne Rovelet-Lecrux; Didier Hannequin; Gregory Raux; Nathalie Le Meur; Annie Laquerrière; Anne Vital; Cécile Dumanchin; Sébastien Feuillette; Alexis Brice; Martine Vercelletto; Frédéric Dubas; Thierry Frebourg; Dominique Campion
Journal:  Nat Genet       Date:  2005-12-20       Impact factor: 38.330

3.  Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease.

Authors:  Jessie Theuns; Nathalie Brouwers; Sebastiaan Engelborghs; Kristel Sleegers; Veerle Bogaerts; Ellen Corsmit; Tim De Pooter; Cornelia M van Duijn; Peter P De Deyn; Christine Van Broeckhoven
Journal:  Am J Hum Genet       Date:  2006-04-10       Impact factor: 11.025

4.  Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression.

Authors:  Y Li; L Liu; J Kang; J G Sheng; S W Barger; R E Mrak; W S Griffin
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

Review 5.  Glia and their cytokines in progression of neurodegeneration.

Authors:  Robert E Mrak; W Sue T Griffin
Journal:  Neurobiol Aging       Date:  2005-03       Impact factor: 4.673

6.  App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome.

Authors:  Anne M Cataldo; Suzana Petanceska; Corrinne M Peterhoff; Nicole B Terio; Charles J Epstein; Angela Villar; Elaine J Carlson; Matthias Staufenbiel; Ralph A Nixon
Journal:  J Neurosci       Date:  2003-07-30       Impact factor: 6.167

7.  Alzheimer's disease in Down's syndrome: clinicopathologic studies.

Authors:  K E Wisniewski; A J Dalton; C McLachlan; G Y Wen; H M Wisniewski
Journal:  Neurology       Date:  1985-07       Impact factor: 9.910

8.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome.

Authors:  K E Wisniewski; H M Wisniewski; G Y Wen
Journal:  Ann Neurol       Date:  1985-03       Impact factor: 10.422

9.  Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease.

Authors:  R E Tanzi; A I McClatchey; E D Lamperti; L Villa-Komaroff; J F Gusella; R L Neve
Journal:  Nature       Date:  1988-02-11       Impact factor: 49.962

10.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  1 in total

1.  Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis.

Authors:  W Sue T Griffin; Steven W Barger
Journal:  US Neurol       Date:  2010
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.